Abstract
A patient-support group, Cancer Patients Aid Association (CPAA, Mumbai, India) has challenged the exclusive marketing rights (EMR) granted by the Indian patent office to Novartis for imatinib for treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours. The EMR were granted as part of the Indian government's commitment to shift to product-patent regimens in 2005.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
